Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tumour cells grow and divide in an uncontrolled fashion. Recent advances in the cell cycle have uncovered new mechanisms that integrate growth and division with chromatin and gene expression control. Small-molecule drugs that target key enzyme classes involved in these pathways, the cyclin-dependent kinases (Cdk) in the cell cycle and histone deacetylases (HDAC) in chromatin control, have entered clinical studies, with emerging clinical efficacy. These new mechanism-based approaches could provide significant improvements over many current chemotherapeutics.

Type

Journal article

Journal

Drug Discov Today

Publication Date

01/09/2003

Volume

8

Pages

793 - 802

Keywords

Animals, Antineoplastic Agents, Cell Cycle, Chromatin, Cyclin-Dependent Kinases, Drug Delivery Systems, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Neoplasms